OLFML2B showed more than 12% amplification in both “BLCA (TCGA 2017)” and “BLCA (Cornrll 2016)” data sets, and more than 7% mutation in “Bladder (DFCI/MSKCC 2014)” data sets (Figure 4C). This evidence concerns the gene OLFML2B and bladder transitional cell carcinoma.